Green, Jeremy,Wilson, Dean M.,Kong, Laval Chan chun,Das, Sanjoy Kumar,Poisson, Carl,Court, John J.,Tang, Qing,Li, Pan,Collier, Philip N.,Waal, Nathan,Lauffer, David J.,Dorsch, Warren
申请号：
AU2011276526
公开号：
AU2011276526A1
申请日:
2011.06.28
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
A compound is represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
